Focus: Parexel is a large CRO headquartered in Boston with 10,001–50,000 employees, providing comprehensive clinical trial and drug development services across early to late-stage programs. The company holds a leading position in clinical trial supplies, packaging, logistics, and end-to-end trial management capabilities.
Profile data last refreshed 16h ago · AI intelligence enriched 1mo ago
Hot — 435 jobs added in 30d
Net +219 (435 new, 216 removed). Aggressive expansion phase.
Strong operational career fit for clinical development, regulatory, and operations professionals seeking stable growth in a market-leading CRO; limited for those seeking product ownership or equity upside.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Parexel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Parexel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Parexel launches Biotech Incubator for early-stage therapeutics - Express Pharma
Parexel launches Biotech Incubator for early-stage therapeutics Express Pharma
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India - Indian Pharma Post
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India Indian Pharma Post
Parexel Launches Parexel Biotech Incubator - Contract Pharma
Parexel Launches Parexel Biotech Incubator Contract Pharma
High-value clinical research marks gradual shift to India: Parexel - Business Standard
High-value clinical research marks gradual shift to India: Parexel Business Standard
Parexel acquires Vitrana to strengthen AI-driven patient safety capabilities - Indian Pharma Post
Parexel acquires Vitrana to strengthen AI-driven patient safety capabilities Indian Pharma Post
Parexel acquires Vitrana to expand pharmacovigilance technology platform - Express Pharma
Parexel acquires Vitrana to expand pharmacovigilance technology platform Express Pharma
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies.
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo